Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
Body composition imaging expertise you can rely on.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
SNMMI 2025 Poster
Authors: Farzaneh Rezazadeh¹, Amira Hussein¹, Jacob Subik¹, Monique Nysus¹, Oslo Stanat¹, Erez Eitan², Ahmed Elsherbini², Amanda Zimmerman³, Ajay Verma³
¹ Perceptive Inc. ² NeuroDex Inc. ³ Formation Venture Engineering Foundry
Background:
Exosomes are extracellular vesicles derived from various cell types that play a crucial role in intercellular communication and have significant potential for diagnostics and therapeutics¹. Recent advances in isolation technologies have enabled the purification and extraction of cell-specific exosomes from plasma. However, understanding the in vivo biodistribution of the different subpopulations of exosomes remains crucial for optimizing their therapeutic application. Zirconium-89 offers a promising tool for positron emission tomography (PET) imaging.
In this study, we labeled both small and large exosome subpopulations with Zirconium-89 to track and evaluate their biodistribution in naïve mice using PET/CT. This research aims to provide valuable insights into the in vivo distribution patterns of differently sized exosomes, which is essential for optimizing their application in diagnostics and therapeutic delivery.
Download now
"*" indicates required fields
Δ
